Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Individuals with non-small cell lung cancer (NSCLC) who possess an epidermal growth factor receptor (EGFR) mutation constitute a distinct subgroup. The cancer’s etiology, clinicopathological characteristics, prognosis, and treatment approaches differ from other NSCLC patients. EGFR mutations are present in 40%–60% of Southeast Asian patients and 10%–20% of Caucasian patients with lung adenocarcinomas. While most EGFR mutation-positive tumors are found in non-smokers or light smokers, this observation is not exclusive. The rising prevalence of non-smoking behavior has led to a higher incidence of EGFR mutations in female patients compared to male patients. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non- or never-smoking lung adenocarcinoma patients, 80% of subjects were female, and 60% of tumors harbored EGFR mutations. Patients diagnosed with metastatic non-small cell lung cancer (NSCLC) carrying EGFR mutations are commonly treated with osimertinib as the preferred first-line option. However, disease progression inevitably occurs due to either EGFR-dependent or EGFR-independent resistance mechanisms. Following progression with osimertinib, platinum-based chemotherapy is the recommended treatment, although responses to such chemotherapy are transient.
Thelansis’s “Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Advanced or Metastatic EGFR-Non-Small Cell Lung Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
